iotaMotion

The Next Wave Of Growth In Surgical Robotics

About this Event

The global surgical robotics market is projected to grow ~15% CAGR to $54B by 2035. One of the most underpenetrated and rapidly emerging applications is cochlear implant surgery, where fewer than 5% of the 60 million implant candidates currently receive treatment.

As robotic technologies expand into increasingly delicate surgical environments, cochlear implantation represents a compelling intersection of unmet clinical need, precision robotics, and long-term platform opportunity.

Join Force Family Office for a fireside discussion exploring the future of robotic-assisted surgery and the emerging role of robotics in hearing restoration with:
  • Matthew O’Brien: Senior Research Analyst and Managing Director for Medical Technology, Piper Sandler
  • Mike Lobinsky: President & CEO, iotaMotion

Discussion Topics:
  • The next wave of growth in surgical robotics
  • Why cochlear implantation represents a significant underserved market
  • How robotic-assisted electrode insertion impacts outcomes
  • The adoption trajectory of precision robotics in ENT procedures

iotaMotion’s iotaSOFT® Robotic-Assisted Cochlear Implant Insertion System enables ultra-slow, controlled electrode insertion that preserves delicate intracochlear structures while ultimately preserving hearing. The system is the first and only FDA-cleared robotic-assisted cochlear implant insertion system.

Watch this fascinating discussion on the future of robotics in medicine.

Video On Demand

– Recorded

March 25

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.